The company is working to establish manufacturing arrangements and a supply chain for its COVID-19 drug candidates to meet demand. It faces competition from Pfizer, Inc., which received FDA approval for Paxlovid, and Merck, in collaboration with Ridgeback Bio, which developed molnupiravir with emergency use authorization. The company acknowledges challenges such as potential viral resistance, competition from therapies that may be more effective or convenient, and the high failure rate in clinical trials. Additionally, larger companies with greater capital and manufacturing infrastructure may affect the company's funding and commercialization prospects. Suppliers mentioned include Merck, Pfizer, Inc., and Ridgeback Bio.
Aligos Therapeutics Inc's Comment on Supply Chain
The company is working to establish manufacturing arrangements and a supply chain for its COVID-19 drug candidates to meet demand. It faces competition from Pfizer, Inc., which received FDA approval for Paxlovid, and Merck, in collaboration with Ridgeback Bio, which developed molnupiravir with emergency use authorization. The company acknowledges challenges such as potential viral resistance, competition from therapies that may be more effective or convenient, and the high failure rate in clinical trials. Additionally, larger companies with greater capital and manufacturing infrastructure may affect the company's funding and commercialization prospects. Suppliers mentioned include Merck, Pfizer, Inc., and Ridgeback Bio.
Sources:
Aligos Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Aligos Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
